“We are on the cusp of the next generation of Cannabis”
CTI Genetics has formed a specialized Plant Molecular Breeding group which utilizes modern genomic tools to unlock the medical potential of Cannabis. Relentless in our pursuit of perfection, CTI Genetics combines genome technologies with traditional breeding practices to augment yields, create defined chemical profiles, and produce active pharmaceutical ingredients which address market needs for medical and pharmaceutical companies.
For thousands of years, Cannabis has been regarded as a plant with numerous beneficial applications, yet the genetic and biochemical profiles of Cannabis have only been summarily explored. CTI plans to uncover the hidden truths within Cannabis while improving yield, quality, and consistency. Leading the CTI genetics team is Chief Science Officer Eric J. Mathur, whose exemplary industrial biotechnology career includes the successful improvement of multiple plants through molecular breeding. His work on the rubber-producing desert shrub, guayule [pronounced why-yoo-lee], resulted in dramatic improvement in yields with significantly increased crop uniformity; his work was publicized by Wired magazine.
Mathur is joined by Dr. Robert J. Schmidt, Vice President of Plant Sciences. Dr. Schmidt is an Emeritus Professor at the University of California, San Diego and an elected Fellow of the American Association for the Advancement of Science. Dr. Schmidt is an expert in plant genetics and a leader in the field of crop improvement and plant domestication. Together, Mathur and Schmidt have over 70 years of combined agricultural breeding and biotechnology expertise.
With improved strain purity that delivers a consistent chemical profile, medicinal attributes will be defined and delivered with agronomic precision. Mathur explains “We’re on the cusp of developing the next generation of Cannabis. CTI’s Cannabis Molecular Breeding program will result in cultivars with high productivity and disease resistance attributes which produce uniform and consistent results. Moreover, the cannabinoid and terpenoids profiles will be dialed in to address specific medical indications .”
Learn more about Cultivation Technologies, Inc. Genetic Improvement Plan
*The business unit includes the wholly-owned subsidiary Plant Innovations, LLC, 75% owned subsidiary DS Gen, LLC, and the mutual benefit corporation Patient Research, Inc.